___

GLOBOCAN: Estimated Cancer Incıdence and Mortality and Prevalence Worldwide in 2012. Available from: http://globocan. iarc.fr

Seiwert TY, Salama JK, Vokes EE. The chemodadition paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156-71.

Bonner JA, Harari PM, Grialt J, Azarnia N, Shin DM, Cohen RB, Jones CU, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006; 354: 567-78.

Vermoken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27

Ang KK, Zhang Q,Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurebt accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma:RTOG 0522. J Clin Oncol 2014; 32: 2940-50.

Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label, phase 2 trial. Lancet Oncol 2015; 16: 20820.

Grialt J,Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 2015; 16: 22132.

Martin RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase 2 trial. J Clin Oncol 2013; 31: 1415-21.

Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, et al. Single-arm phase 2 study of multiagent concurent chemotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Wiley Online Library 2011; 34: 1517-23.

Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase 2, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011; 100 :62-9.

Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Afatinin versus placebo as adjuvant therapy after chemoradiation in double-blind, phase 3 study(LUX-Head&Neck 2) in patients with primary unresected, clinically intermediate-to-highrisk head and neck cancer:study protocol for a randomized controlled trial. Trials 2014; 15: 469.